Search PubMed⌕ Search

Biomedical subjects

D Rosner

Publications and source records attributed to D Rosner.

At least 91 records · Page 5Linked to original sources
PubMed1978

Visualization of breast lesions with an advanced ultrasonic device: results of a pilot study.

A pilot study is described in which a new design of a sensitive ultrasonic device was used to visualize breast lesions in nine patients. The results were in general accord with clinical, histologic, and x-ray examinations, although ultrasound was superior to x-ray mammography in the visualization of discrete cysts in breasts having a "dense" background. As the device provides an indication of the capabilities of ultrasonic equipment which will be generally available within the next two years, projections are made on the impact of this equipment on the earlier diagnosis and prognosis of cancer, together with a discussion of the negligible radiation bio-hazards posed by devices of this type, in the light of present knowledge.

Adenocarcinoma↗
PubMed1976

Combination chemotherapy in the treatment of advanced breast cancer.

Seventy-two women with metastatic breast cancer were treated with multiple-agent chemotherapy. Fifty women were treated with 5 drugs in combination: 5-FU, methotrexate, vincristine, cytoxan, and prednisone; 22 were treated with the combination of 3 drugs: 5-fu, cytoxan, and prednisone. In 14 patients receiving 5 drugs and in 22 receiving 3 drugs, the multiple chemotherapy was the primary palliative treatment of extensive visceral metastases unsuitable for adrenalectomy. Results were similar with 6 responders in 14 (0.43) receiving 5 drugs, and 10 responders in 22 (0.45) receiving 3 drugs. The remaining 36 patients who were given 5-drug therapy all had previous adrenalectomy, and there were 16 responders (0.44). Toxicities from 3-drug treatment were substantially less severe than those from the 5-drug combination therapy. Whereas treatment-related death occurred in 6 of 50 patients receiving the 5-drug combination, no such incidence occurred in those receiving 3-drug combination therapy.

Adrenalectomy↗
PubMed1976

Immunotherapy for accessible tumors utilizing delayed hypersensitivity reactions and separated components of the immune system.

Courses of repeated delayed hypersensitivity challenge reactions at the sites of tumors have been shown to eradicate malignant and premalignant epidermal neoplasms. Local immunotherapy produces therapeutic responses in malignant and premalignant lesions before they are clinically detectable. This leads to a reduced incidence and prevention of tumors. Immunotherapeutic approaches are effective in controlling the early stages of mycosis fungoides and may aid in the management of the cutaneous manifestations in the late stages of the disease. Immunotherapeutic methods induce regressions of soft tissue lesions of a number of multifocal or metastatic malignant diseases with or without concurrent chemotherapy. Immunotherapeutic effects on tumors are similar with primary and recall antigens. Separated components of the cell-mediated immune system induce regressions of tumors following intralesional or perilesional administration, indicating common factors in host defenses against malignant diseases.

Administration, Topical↗
PubMed1976

Discussion paper: effect of supernatants from long-term lymphoid cell lines on metastatic cutaneous tumors following local injection.

A fraction with lymphokine properties was isolated from supernatant medium of the continuous cultured human lymphoblast cell line, 1788. Culture medium containing 2% human serum was used for cell growth in order to minimize antigenicity of supernatant fractions isolated from the medium. The culture medium was passed through an Amicon XM-100 membrane, concentrated over a PM-10 membrane, lyophilized, and reconstituted to a final concentration of approximately 40:1. Studies in vivo and in vitro showed that the active fraction contained skin reactive factor (when injected intradermally into guinea pigs and humans), lymphotoxin, migration inhibition factor, chemotactic factor, and macrophage activation factor. This same preparation, when injected intralesionally into cutaneous tumors, induced an inflammatory reaction followed by tumor regression. The fraction confined between membranes of pore size 10,000-100,000 daltons was active in promoting tumor regression, while the fraction less than 10,000 daltons was inactive. Patients with skin lesions from metastatic carcinoma of the breast and other malignancies were studied, and 16 out of 30 treated lesions were judged to have undergone either complete or greater than 50% regression. Of these, 8 were biopsied before and after lymphokine injection, and 6 out of 9 were negative for tumor cells. Additional studies in vitro with material fractionated on Sephadex G-200 indicated that the macrophage-activating component binds to alpha-2 macroglobulin in the culture medium.

Acid Phosphatase↗
PubMed1976

Nonspecific antigen reactions.

Cell-mediated immune challenge reactions to a number of antigens at tumor sites resulted in regressions of various types of benign, premalignant, and malignant lesions in man. Regressions varied from partial to complete and lasted from several months to more than 10 years. Increased levels of cell-mediated immunocompetence were attained by several means, including reduction of tumor burden, immunopotentiation, or transfer of immunity. Antitumor activities of immune challenge reactions are selective for tumor cells and appear to be independent of the nature of the antigens used or the type of neoplasm. Combinations of immunotherapy with other treatment modalities resulted in augmentation of antitumor effects. Preliminary studies indicate that cellular and noncellular mediators of delayed hypersensitivity induce antitumor activities that may be significant in the regressions of neoplasms induced by cell-mediated immune challenge reactions. Since cell-mediated immune reactions are frequent occurrences, they may be a factor in apparently spontaneous regressions of neoplasms.

Administration, Topical↗
PubMed1975

Regression of cutaneous neoplasms following delayed-type hypersensitivity challenge reactions to microbial antigens or lymphokines.

Induction of delayed-type hypersensitivity challenge reactions to microbial antigens at sites of neoplasms involving the skin resulted in regression of mycosis fungoides, reticulum cell sarcoma, superficial basal cell carcinoma and adenocarcinoma of the breast. Similar reactions induced by lymphokine preparations also resulted in regression of lesions of mycosis fungoides and superficial basal cell carcinoma. The role of the large monomuclear cells in the inflammatory infiltrate of the delayed hypersensitivity reaction in eliciting the tumor regression is discussed. It is proposed that these large mononuclear cells represent the effectors in a primitive surveillance mechanism for neoplastic cells.

Adenocarcinoma↗